Creso Pharma’s Mernova receives esteemed award
In a development that will effectively make Creso Pharma Limited (ASX:CPH, FRA: 1X8) wholly-owned Canadian subsidiary Mernova Medicinal Inc. one of a select group of licensed cannabis producers the group has been awarded Craft Designation by the Ontario Cannabis Store (OCS).
The OCS is a crown agency solely owned by the Province of Ontario, and it reports directly to the Ministry of Finance, being the province’s only retailer and wholesaler of legal recreational cannabis.
The OCS has created a specific category for craft cannabis products available to consumers in Ontario.
To qualify, dried-flower and pre-roll products must be hand-trimmed, hang-dried and hand-packaged.
Mernova’s managing director Jack Yu was praiseworthy of his operational team in terms of their commitment to optimum quality production control in saying, “Our focus has always been on quality over all else and being awarded OCS Craft Designation is a direct result of this strategy.
"To be one of the only companies to be awarded OCS Craft Designation in Ontario is a major validation of the hard work and effort put in by our operations team, and it reflects the resulting artisanal quality of our products.
‘’We do things the right way, combining science and artisanal methods to produce some of the finest cannabis available.
‘’We don’t compromise on quality, and we’re becoming recognised within the industry because of it.’’
Award is expected to provide competitive advantages
This designation is an important achievement for Mernova and will provide Creso Pharma with much broader visibility in a competitive market.
It also highlights the superior quality of Mernova’s products as the company continues to achieve strong sales growth across Ontario.
On this note, Yu said, "We are confident that this new category will help further differentiate us from the competition, enhance our brand, and provide increased brand exposure and brand awareness, which should result in much broader visibility within the market.”
Currently, Mernova’s HPG13, Lemon Haze, and Clementine Punch strains are sold out across multiple dispensaries in the province.
Ontario represents a large addressable market for Creso Pharma, and as it is one of the largest recreational cannabis markets in Canada there is an expectation of Mernova achieving ongoing growth through the region.
Ritual Green products are currently available to over 600 stores in Ontario, while also being available to the public directly through the OCS online sales platform.
Management is continuing to monitor potential patterns and shifts in the distribution of cannabis in Ontario in order to adjust to the varying dynamics.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.